Laurence Peiperl
Research Subjects
Laurence Peiperl has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Abraham Haileamlak
10Editor-in-Chief, Ethiopian Journal of Health Sciences
1 shared publication- Anja Pinborg
Fertility Clinic, Department of Gynecology, Fertility and Obstetrics, Rigshospitalet, Copenhagen University Hospital , Copenhagen
1 shared publication - Astrid James
The Lancet, London EC2Y 5AS, UK
1 shared publication Ayumi Shintani
Department of Biostatistics, Vanderbilt University, Nashville, Tennessee
1 shared publicationBarney S. Graham
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
1 shared publicationCecilia Morgan
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
1 shared publication
Latest Publications
- Open Access
- 20 January 2016
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 129 (2) , 127-128
Sharing Clinical Trial Data
- 20 January 2016
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 129 (2) , 127-128
Open AccessSharing Clinical Trial Data
- Open Access
- 29 July 2014
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 11 (7) , e1001682
Blue Marble Health: A Call for Papers
In this month's editorial, Peter J. Hotez, Co-Editor-in-Chief of PLOS Neglected Tropical Diseases and Larry Peiperl, Chief Editor of PLOS Medicine, call for papers on “Blue Marble Health”: research on health problems that affect poorer people irrespective of the overall economic strength of the countries in which they live. Please see later in the article for the Editors' Summary
- 29 July 2014
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 11 (7) , e1001682
Open AccessBlue Marble Health: A Call for Papers
In this month's editorial, Peter J. Hotez, Co-Editor-in-Chief of PLOS Neglected Tropical Diseases and Larry Peiperl, Chief Editor of PLOS Medicine, call for papers on “Blue Marble Health”: research on health problems that affect poorer people irrespective of the overall economic strength of the countries in which they live. Please see later in the article for the Editors' Summary
- Open Access
- 27 October 2010
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (10) , e13579
Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)
Individuals without prior immunity to a vaccine vector may be more sensitive to reactions following injection, but may also show optimal immune responses to vaccine antigens. To assess safety and maximal tolerated dose of an adenoviral vaccine vector in volunteers without prior immunity, we evaluated a recombinant replication-defective adenovirus type 5 (rAd5) vaccine expressing HIV-1 Gag, Pol, and multiclade Env proteins, VRC-HIVADV014-00-VP, in a randomized, double-blind, dose-escalation, multicenter trial (HVTN study 054) in HIV-1-seronegative participants without detectable neutralizing antibodies (nAb) to the vector. As secondary outcomes, we also assessed T-cell and antibody responses. Volunteers received one dose of vaccine at either 1010 or 1011 adenovector particle units, or placebo. T-cell responses were measured against pools of global potential T-cell epitope peptides. HIV-1 binding and neutralizing antibodies were assessed. Systemic reactogenicity was greater at the higher dose, but the vaccine was well tolerated at both doses. Although no HIV infections occurred, commercial diagnostic assays were positive in 87% of vaccinees one year after vaccination. More than 85% of vaccinees developed HIV-1-specific T-cell responses detected by IFN-γ ELISpot and ICS assays at day 28. T-cell responses were: CD8-biased; evenly distributed across the three HIV-1 antigens; not substantially increased at the higher dose; and detected at similar frequencies one year following injection. The vaccine induced binding antibodies against at least one HIV-1 Env antigen in all recipients. This vaccine appeared safe and was highly immunogenic following a single dose in human volunteers without prior nAb against the vector. ClinicalTrials.gov NCT00119873
- 27 October 2010
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (10) , e13579
Open AccessSafety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)
Individuals without prior immunity to a vaccine vector may be more sensitive to reactions following injection, but may also show optimal immune responses to vaccine antigens. To assess safety and maximal tolerated dose of an adenoviral vaccine vector in volunteers without prior immunity, we evaluated a recombinant replication-defective adenovirus type 5 (rAd5) vaccine expressing HIV-1 Gag, Pol, and multiclade Env proteins, VRC-HIVADV014-00-VP, in a randomized, double-blind, dose-escalation, multicenter trial (HVTN study 054) in HIV-1-seronegative participants without detectable neutralizing antibodies (nAb) to the vector. As secondary outcomes, we also assessed T-cell and antibody responses. Volunteers received one dose of vaccine at either 1010 or 1011 adenovector particle units, or placebo. T-cell responses were measured against pools of global potential T-cell epitope peptides. HIV-1 binding and neutralizing antibodies were assessed. Systemic reactogenicity was greater at the higher dose, but the vaccine was well tolerated at both doses. Although no HIV infections occurred, commercial diagnostic assays were positive in 87% of vaccinees one year after vaccination. More than 85% of vaccinees developed HIV-1-specific T-cell responses detected by IFN-γ ELISpot and ICS assays at day 28. T-cell responses were: CD8-biased; evenly distributed across the three HIV-1 antigens; not substantially increased at the higher dose; and detected at similar frequencies one year following injection. The vaccine induced binding antibodies against at least one HIV-1 Env antigen in all recipients. This vaccine appeared safe and was highly immunogenic following a single dose in human volunteers without prior nAb against the vector. ClinicalTrials.gov NCT00119873
- 1 January 2008
- Published by Elsevier
- p. 725-736
Selected NGOs Active in HIV and Web Links
- 1 September 2006
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 194 (5) , 661-665
Low CD4+T Cell Nadir Is an Independent Predictor of Lower HIV‐Specific Immune Responses in Chronically HIV‐1–Infected Subjects Receiving Highly Active Antiretroviral Therapy
The influence of CD4+ T cell nadirs on human immunodeficiency virus (HIV)–specific immune responses in subjects with apparently normal CD4+ T cell counts is not known. We evaluated the frequency of HIV-1–specific immune responses in a cohort of patients with complete viral suppression (HIV-1 RNA load, + T cell nadirs. We found positive associations between CD4+ T cell nadirs and the magnitude of HIV-specific CD8+ T cell responses (P=.02) and of T cell helper responses (P=.04). These data show the CD4+ T cell nadir to be an independent predictor of HIV-specific CD4+ and CD8+ T cell responses in HIV-1–infected subjects with optimal suppression of viremia
- 1 September 2006
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 194 (5) , 661-665
Low CD4+T Cell Nadir Is an Independent Predictor of Lower HIV‐Specific Immune Responses in Chronically HIV‐1–Infected Subjects Receiving Highly Active Antiretroviral Therapy
The influence of CD4+ T cell nadirs on human immunodeficiency virus (HIV)–specific immune responses in subjects with apparently normal CD4+ T cell counts is not known. We evaluated the frequency of HIV-1–specific immune responses in a cohort of patients with complete viral suppression (HIV-1 RNA load, + T cell nadirs. We found positive associations between CD4+ T cell nadirs and the magnitude of HIV-specific CD8+ T cell responses (P=.02) and of T cell helper responses (P=.04). These data show the CD4+ T cell nadir to be an independent predictor of HIV-specific CD4+ and CD8+ T cell responses in HIV-1–infected subjects with optimal suppression of viremia
- 1 January 2005
- Published by Elsevier
- p. 162-189
Challenges in Developing HIV Vaccines
- 1 February 2001
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 2 (1) , 46-55
Antiretroviral Treatments to Reduce Mother-to-Child Transmission of HIV
- 1 February 2001
- Published by Taylor & Francis in HIV Research & Clinical Practice
- Vol. 2 (1) , 46-55
Antiretroviral Treatments to Reduce Mother-to-Child Transmission of HIV
- 1 March 1994
- Vol. 160 (3) , 252-3
Tuberculosis and human immunodeficiency virus disease.
- 1 July 1991
- Published by Oxford University Press (OUP) in American Review of Respiratory Disease
- Vol. 144 (1) , 6-9
Morbidity and Mortality of Patients with AIDS and First-Episode Pneumocystis carinii Pneumonia Unaffected by Concomitant Pulmonary Cytomegalovirus Infection
To determine the significance of cytomegalovirus (CMV) pulmonary confection with Pneumocystis carinii pneumonia in AIDS, we examined the association of long- and short-term survival and morbidity (as defined by length of hospital stay) with recovery of CMV from bronchoscopy specimens and an indirect measure of virus titer in bronchoalveolar lavage fluid (the time to develop CMV cytopathology in culture) in 111 patients diagnosed with a first episode of P. carinii pneumonia. Compared with 57 individuals from whom CMV was not isolated, the 54 individuals from whom CMV were isolated did not differ in baseline characteristics, long-term survival (213 versus 275 days, p = 0.97), acute death rate (19% in both, p = 1.0), or length of hospital stay (19.7 versus 21.1 days, p = 0.68). Also, the time to develop CMV cytopathology in culture did not correlate with acute or long-term survival. Our observations thus do not support the use of CMV-specific antiviral therapy in AIDS patients with P. carinii pneumonia who also have evidence of pulmonary CMV infection.
- 1 July 1991
- Published by Oxford University Press (OUP) in American Review of Respiratory Disease
- Vol. 144 (1) , 6-9
Morbidity and Mortality of Patients with AIDS and First-Episode Pneumocystis carinii Pneumonia Unaffected by Concomitant Pulmonary Cytomegalovirus Infection
To determine the significance of cytomegalovirus (CMV) pulmonary confection with Pneumocystis carinii pneumonia in AIDS, we examined the association of long- and short-term survival and morbidity (as defined by length of hospital stay) with recovery of CMV from bronchoscopy specimens and an indirect measure of virus titer in bronchoalveolar lavage fluid (the time to develop CMV cytopathology in culture) in 111 patients diagnosed with a first episode of P. carinii pneumonia. Compared with 57 individuals from whom CMV was not isolated, the 54 individuals from whom CMV were isolated did not differ in baseline characteristics, long-term survival (213 versus 275 days, p = 0.97), acute death rate (19% in both, p = 1.0), or length of hospital stay (19.7 versus 21.1 days, p = 0.68). Also, the time to develop CMV cytopathology in culture did not correlate with acute or long-term survival. Our observations thus do not support the use of CMV-specific antiviral therapy in AIDS patients with P. carinii pneumonia who also have evidence of pulmonary CMV infection.
- 1 February 1990
- Published by Wiley in Transfusion
- Vol. 30 (2) , 133-137
Red cell transfusion therapy for anemia in patients with AIDS and ARC: incidence, associated factors, and outcome
The records of the San Francisco General Hospital (SFGH) Blood Bank were reviewed, and 263 likely AIDS and AIDS‐related complex (ARC) patients were identified, who received 1545 units of packed red cells (PBRCs) between July 1, 1987, and June 30, 1988. A probability sample of 80 of these patients was selected randomly for detailed chart review. Of this sample, 78 (98%) were confirmed to have AIDS (86%) or ARC (14%). On the basis of the yearly census of the SFGH AIDS clinic, a transfusion incidence of 0.89 PRBC units per patient per year for patients with AIDS and 0.27 PRBC units per patient per year for those with ARC was estimated. Whereas 26 percent of the 177 transfusions studied in detail involved more than one associated (possibly causative) factor, antimicrobial drug therapy, zidovudine therapy, and disseminated Mycobacterium avium complex (MAC) infection were the sole associated factors in 20, 14, and 12 percent of the transfusions, respectively. To assess the role of MAC, the 263 transfused patients were compared with the 574 patients whose blood was submitted to the SFGH Mycobacteriology Laboratory during the same period. Patients whose blood yielded MAC had a relative risk of 5.2 for transfusion‐requiring anemia. In 80 percent of cases, the patient returned home after transfusion. Most PRBC transfusions administered to AIDS or ARC patients were optimal therapy.
- 1 February 1990
- Published by Wiley in Transfusion
- Vol. 30 (2) , 133-137
Red cell transfusion therapy for anemia in patients with AIDS and ARC: incidence, associated factors, and outcome
The records of the San Francisco General Hospital (SFGH) Blood Bank were reviewed, and 263 likely AIDS and AIDS‐related complex (ARC) patients were identified, who received 1545 units of packed red cells (PBRCs) between July 1, 1987, and June 30, 1988. A probability sample of 80 of these patients was selected randomly for detailed chart review. Of this sample, 78 (98%) were confirmed to have AIDS (86%) or ARC (14%). On the basis of the yearly census of the SFGH AIDS clinic, a transfusion incidence of 0.89 PRBC units per patient per year for patients with AIDS and 0.27 PRBC units per patient per year for those with ARC was estimated. Whereas 26 percent of the 177 transfusions studied in detail involved more than one associated (possibly causative) factor, antimicrobial drug therapy, zidovudine therapy, and disseminated Mycobacterium avium complex (MAC) infection were the sole associated factors in 20, 14, and 12 percent of the transfusions, respectively. To assess the role of MAC, the 263 transfused patients were compared with the 574 patients whose blood was submitted to the SFGH Mycobacteriology Laboratory during the same period. Patients whose blood yielded MAC had a relative risk of 5.2 for transfusion‐requiring anemia. In 80 percent of cases, the patient returned home after transfusion. Most PRBC transfusions administered to AIDS or ARC patients were optimal therapy.